Mind Medicine Inc has a consensus price target of $19.33, established from looking at the 36 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, HC Wainwright & Co., and Leerink Partners on May 13, 2024, May 10, 2024, and April 15, 2024. With an average price target of $25 between Oppenheimer, HC Wainwright & Co., and Leerink Partners, there's an implied 209.41% upside for Mind Medicine Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/13/2024 | Buy Now | 147.52% | Oppenheimer | Francois Brisebois | $29 → $20 | Reiterates | Outperform → Outperform | Get Alert |
05/10/2024 | Buy Now | 333.17% | HC Wainwright & Co. | Patrick Trucchio | $75 → $35 | Maintains | Buy | Get Alert |
04/15/2024 | Buy Now | 147.52% | Leerink Partners | Rudy Li | → $20 | Initiates | → Outperform | Get Alert |
03/14/2024 | Buy Now | 828.22% | HC Wainwright & Co. | Patrick Trucchio | → $75 | Reiterates | Buy → Buy | Get Alert |
03/08/2024 | Buy Now | 172.28% | RBC Capital | Brian Abrahams | $15 → $22 | Maintains | Outperform | Get Alert |
03/07/2024 | Buy Now | 345.54% | Roth MKM | Jonathan Aschoff | $25 → $36 | Maintains | Buy | Get Alert |
03/01/2024 | Buy Now | 828.22% | HC Wainwright & Co. | Patrick Trucchio | → $75 | Reiterates | Buy → Buy | Get Alert |
02/29/2024 | Buy Now | 85.64% | RBC Capital | Brian Abrahams | $14 → $15 | Maintains | Outperform | Get Alert |
10/23/2023 | Buy Now | -13.37% | RBC Capital | Brian Abrahams | → $7 | Reiterates | Outperform → Outperform | Get Alert |
08/22/2023 | Buy Now | -13.37% | Cantor Fitzgerald | Charles Duncan | → $7 | Reiterates | Overweight → Overweight | Get Alert |
08/04/2023 | Buy Now | 828.22% | HC Wainwright & Co. | Patrick Trucchio | → $75 | Reiterates | → Buy | Get Alert |
08/04/2023 | Buy Now | -13.37% | RBC Capital | Brian Abrahams | $5 → $7 | Maintains | Outperform | Get Alert |
08/04/2023 | Buy Now | 159.9% | EF Hutton | Elemer Piros | → $21 | Reiterates | Buy → Buy | Get Alert |
07/10/2023 | Buy Now | -38.12% | RBC Capital | Brian Abrahams | → $5 | Reiterates | Outperform → Outperform | Get Alert |
06/28/2023 | Buy Now | 828.22% | HC Wainwright & Co. | Patrick Trucchio | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
06/21/2023 | Buy Now | -38.12% | RBC Capital | Brian Abrahams | — | Reiterates | Outperform → Outperform | Get Alert |
06/20/2023 | Buy Now | 159.9% | EF Hutton | Elemer Piros | → $21 | Reiterates | Buy → Buy | Get Alert |
05/18/2023 | Buy Now | -13.37% | Cantor Fitzgerald | Charles Duncan | → $7 | Reiterates | → Overweight | Get Alert |
05/18/2023 | Buy Now | 159.9% | EF Hutton | Elemer Piros | → $21 | Reiterates | Buy → Buy | Get Alert |
05/09/2023 | Buy Now | 828.22% | HC Wainwright & Co. | Patrick Trucchio | → $75 | Reiterates | → Buy | Get Alert |
05/05/2023 | Buy Now | 159.9% | EF Hutton | Elemer Piros | → $21 | Reiterates | → Buy | Get Alert |
04/18/2023 | Buy Now | 828.22% | HC Wainwright & Co. | Patrick Trucchio | → $75 | Reiterates | → Buy | Get Alert |
04/14/2023 | Buy Now | 172.28% | Oppenheimer | Francois Brisebois | → $22 | Reiterates | → Outperform | Get Alert |
04/14/2023 | Buy Now | 159.9% | EF Hutton | Elemer Piros | → $21 | Reiterates | → Buy | Get Alert |
03/16/2023 | Buy Now | 828.22% | HC Wainwright & Co. | Patrick Trucchio | → $75 | Reiterates | → Buy | Get Alert |
03/10/2023 | Buy Now | -38.12% | RBC Capital | Brian Abrahams | → $5 | Reiterates | → Outperform | Get Alert |
03/10/2023 | Buy Now | 159.9% | EF Hutton | Elemer Piros | → $21 | Reiterates | → Buy | Get Alert |
01/19/2023 | Buy Now | 828.22% | HC Wainwright & Co. | Patrick Trucchio | → $75 | Reiterates | → Buy | Get Alert |
12/16/2022 | Buy Now | 159.9% | EF Hutton | Elemer Piros | → $21 | Initiates | → Buy | Get Alert |
11/16/2022 | Buy Now | -38.12% | RBC Capital | Brian Abrahams | → $5 | Initiates | → Outperform | Get Alert |
The latest price target for Mind Medicine (NASDAQ: MNMD) was reported by Oppenheimer on May 13, 2024. The analyst firm set a price target for $20.00 expecting MNMD to rise to within 12 months (a possible 147.52% upside). 17 analyst firms have reported ratings in the last year.
The latest analyst rating for Mind Medicine (NASDAQ: MNMD) was provided by Oppenheimer, and Mind Medicine reiterated their outperform rating.
There is no last upgrade for Mind Medicine.
There is no last downgrade for Mind Medicine.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mind Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mind Medicine was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
While ratings are subjective and will change, the latest Mind Medicine (MNMD) rating was a reiterated with a price target of $29.00 to $20.00. The current price Mind Medicine (MNMD) is trading at is $8.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.